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Expanded Abstract 
Citation 
Steinberg KP, Hudson LD, Goodman RB, Hough CL, 
Lanken PN, Hyzy R, Thompson BT, Ancukiewicz M: 
Efficacy and safety of corticosteroids for persistent acute 
respiratory distress syndrome. N Engl J Med 2006, 
354:1671-1684 [1]. 
Background 
Persistent acute respiratory distress syndrome (ARDS) is 
characterized by excessive fibroproliferation, ongoing 
inflammation, prolonged mechanical ventilation, and a 
substantial risk of death. Because previous reports 
suggested that corticosteroids may improve survival, the 
study authors performed a multicenter, randomized 
controlled trial of corticosteroids in patients with persistent 
ARDS. 
Methods 
Objective: To determine if low dose corticosteroids would 
improve survival among patients with persistent ARDS. 
Design: Multicenter randomized controlled trial. 
Setting: 25 hospitals in the United States that were part of 
the ARDS Clinical Trials Network. 
Subjects: 180 mechanically ventilated patients with ARDS 
of at least seven days duration. 
Intervention:  Subjects were randomized to either 
intravenous methylprednisolone (steroid group) or placebo 
in a double-blind fashion. Those in the steroid group 
received 2 mg/kg loading dose followed by 0.5 mg/kg every 
6 hours for 14 days, 0.5 mg/kg every 12 hours for 7 days, 
and then tapering of the dose over 2-4 days.  
Measurements and main results: The primary end point 
was mortality at 60 days. Secondary end points included the 
number of ventilator-free days and organ-failure-free days, 
biochemical markers of inflammation and fibroproliferation, 
and infectious complications. At 60 days, the hospital 
mortality rate was 28.6 percent in the placebo group (95 
percent confidence interval, 20.3 to 38.6 percent) and 29.2 
percent in the methylprednisolone group (95 percent 
confidence interval, 20.8 to 39.4 percent; P=1.0); at 180 
days, the rates were 31.9 percent (95 percent confidence 
interval, 23.2 to 42.0 percent) and 31.5 percent (95 percent 
confidence interval, 22.8 to 41.7 percent; P=1.0), 
respectively. Methylprednisolone was associated with 
significantly increased 60- and 180-day mortality rates 
among patients enrolled at least 14 days after the onset of 
ARDS. Methylprednisolone increased the number of 
ventilator-free and shock-free days during the first 28 days 
in association with an improvement in oxygenation, 
respiratory-system compliance, and blood pressure with 
fewer days of vasopressor therapy. As compared with 
placebo, methylprednisolone did not increase the rate of 
infectious complications but was associated with a higher 
rate of neuromuscular weakness. 
Conclusion 
These results do not support the routine use of 
methylprednisolone for persistent ARDS despite the 
improvement in cardiopulmonary physiology. In addition, 
starting methylprednisolone therapy more than two weeks 
after the onset of ARDS may increase the risk of death. 
(ClinicalTrials.gov number, NCT00295269.) 
Commentary 
ARDS is a condition characterized by excessive and 
protracted inflammation. The lung inflammation observed in 
ARDS can be precipitated by diverse disease processes, 
including both intrapulmonary ones (such as, infection or 
aspiration) and extrapulmonary ones (such as, shock or 
extensive trauma). In the early (<7 days) stages of ARDS, 
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an exudative inflammation is thought to predominate. In 
later stages (>7 days), a fibroproliferative phase may 
develop. Each of these two inflammatory phases has been 
considered potentially amenable to the anti-inflammatory 
effects of corticosteroid (steroid) therapy.  
Short courses of high doses of steroids in ARDS are not 
beneficial [2,3]. More recently, it has been suggested that 
lower doses of steroid (1-2 mg/kg/day) for a more prolonged 
period might benefit the lung while reducing the potential for 
systemic side-effects. Recent data from a retrospective 
subgroup analysis of a clinical trial [4] and a small (n=91) 
prospective clinical trial [5] suggest that such an approach 
may improve outcomes, including mortality, in early ARDS. 
In late ARDS, initial observational studies also suggested 
benefit [6,7]. Subsequently, in 1998, Meduri and colleagues 
reported dramatically lower ICU (0% vs 62%, p=0.002) and 
hospital (12% vs 62%, p=0.03) mortality in a small (n=24) 
randomized study of low dose steroids in patients who had 
severe ARDS for 7 days [8].  
Based on the promising results in late ARDS, the ARDS 
Clinical Trials Network conducted the current study, which 
was a multicenter randomized trial of low dose steroids in 
180 patients with ARDS of at least 7 days duration [1]. In 
this study, the steroid treated group received intravenous 
methylprednisolone (2 mg/kg/day) for 14 days. The dose 
was then decreased to 1 mg/kg/day for 7 more days, and 
then tapered to zero over 2-4 days. Steroid treated subjects 
had significantly reduced lung inflammation, improved 
oxygenation, better respiratory-system compliance, and 
more ventilator-free and shock-free days during the first 28 
days. However, 60 and 180 day mortality rates in each 
group were almost identical (29.2% vs. 28.6% and 31.5% 
vs. 31.9%, steroids vs. placebo). There were no differences 
in infectious complications, but there was a higher rate of 
neuromuscular weakness in the steroid group. In the subset 
of patients enrolled at least 14 days after the onset of 
ARDS, steroids were associated with significantly worse 60 
and 180 day mortality. Yet, in those enrolled between 7 and 
13 days of ARDS onset, mortality was non-significantly 
lower with steroids.  
Although this was a large and well conducted study, a 
number of criticisms have been raised. The study was 
conducted over a period of time when there were 
substantial changes in ICU practice, including low tidal 
volume ventilation, tight blood glucose control, and steroids 
for refractory septic shock. Even so, the authors did not find 
an interaction between period of time or baseline tidal 
volume and outcome, suggesting that secular trends did not 
obscure a beneficial steroid effect. The study had a large 
number of exclusion criteria, which resulted in only 5% of 
otherwise eligible patients being enrolled. While this could 
affect the generalizability of the study, it is not uncommon in 
ICU-based clinical trials. The methylprednisolone was 
tapered relatively quickly (over 2-4 days), which might have 
led to rebound pulmonary inflammation [9]. This premise is 
supported by greater reintubation rates in steroid treated 
subjects (22% vs. 7%), though neuromyopathy could also 
be responsible for this latter finding. The treatment group 
contained a disproportionate number of females, and 
females have previously been shown to be less responsive 
to corticosteroid therapy [10], perhaps because of a greater 
capacity to metabolize methylprednisolone compared to 
males [11]. However, the interactions between gender, 
treatment assignment, and outcome were not significant.  
It is perhaps surprising that while steroids had beneficial 
short-term effects, such as reduced inflammation and 
improved physiologic measures, this did not translate into 
improved mortality. Yet the literature is full of examples 
where short-term effects and surrogate endpoints fail to 
predict long-term clinical outcomes [12] (table). 
Table: Surrogate vs. clinical outcomes 
Intervention Disease  Surrogate Clinical  Outcome 
Growth 
hormone 
Critical 
illness 
↑ nitrogen 
balance 
↑ mortality [13] 
Milrinone CHF  ↑ exercise   ↑ mortality [14,15] 
Flecanide Post-AMI  ↓ arrhythmias  ↑ mortality [16,17] 
Transfusion ICU  anemia ↑ hematocrit  ↑ mortality [18] 
Inhaled 
nitric oxide 
ARDS  ↑ oxygenation  No mortality 
benefit [19] 
Surfactant ARDS  ↑ oxygenation  No mortality 
benefit [20] 
CHF = congestive heart failure; AMI = acute myocardial infarction;           
ICU = intensive care unit; ARDS = Acute respiratory distress syndrome 
Such disparate findings do not indicate a failed clinical trial. 
In fact, protocol dictates that after in vivo biology has been 
demonstrated and efficacy inferred by improvements in 
surrogate measures, definitive studies should seek 
evidence of benefit using end points that measure 
important, patient-centered outcomes, including 
intermediate and longer term survival [21]. Clearly, the 
authors of the current study followed the established 
paradigm. Their findings should serve to remind us that 
while we may be eager to embrace the latest treatment 
advances, we should always maintain a skeptic’s eye. 
Recommendation 
Prolonged low dose corticosteroids are not beneficial for the 
treatment of late ARDS and may be harmful for patients 
when initiated more than 14 days after the onset of ARDS. 
There may be a window of opportunity for further study of 
low dose steroids in late ARDS in patients who are within 7-
13 days of disease onset. This distinction, however, is 
somewhat arbitrary and the optimum time to intervene might 
be better guided by as yet unidentified measures of 
pulmonary and systemic immune status. 
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